There are 2949 resources available
83MO - Co-occurrence of actionable gene fusions and microsatellite instability-high (MSI-H) in 20296 solid tumors: A pan-cancer analysis
Presenter: Tao Fu
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
84MO - Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups
Presenter: Yan Asmann
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
85MO - Pan-cancer analysis of homologous recombination (HR)-associated alterations (alts) and genome-wide loss of heterozygosity (gLOH)
Presenter: Christoph Benedikt Westphalen
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
86MO - Personalized molecularly matched therapies for carcinomas of unknown primary is associated with improved outcomes
Presenter: Jacob Adashek
Session: Mini Oral - Translational research
Resources:
Abstract
Slides
Webcast
1237MO - SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
Presenter: Sacha Rothschild
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA21 - Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial
Presenter: Christophe Borg
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
400MO - Curative chemoradiation for low rectal cancer: Early clinical outcomes from a multicentre phase II trial
Presenter: Lars Henrik Jensen
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
401MO - OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage III colon cancer patients: A randomized phase III ACHIEVE trial
Presenter: Takayuki Yoshino
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
402MO - Final results of the CARACAS study: Randomized phase II trial of avelumab alone or with cetuximab for unresectable, locally advanced or metastatic squamous cell anal carcinoma progressed to at least one line of treatment
Presenter: Sara Lonardi
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast
403MO - Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer
Presenter: Van Morris
Session: Mini Oral - Gastrointestinal tumours, colorectal
Resources:
Abstract
Slides
Webcast